Literature DB >> 15986018

Diagnosis and treatment of primary glomerular diseases. Membranous nephropathy, focal segmental glomerulosclerosis and IgA nephropathy.

J K J Deegens1, J F M Wetzels.   

Abstract

Membranous nephropathy, focal segmental glomerulosclerosis (FSGS) and IgA nephropathy are the most frequent and important primary glomerulopathies. Idiopathic membranous nephropathy and primary FSGS usually present with a nephrotic syndrome with or without renal insufficiency, whereas IgA nephropathy is more often characterized by (symptomless) hematuria and proteinuria. Although the outcome of these glomerulopathies is quite variable, many patients will progress to end-stage renal disease. In this review we discuss several aspects of the primary glomerulopathies with emphasis on the potential benefit of specific immunosuppressive regimens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15986018

Source DB:  PubMed          Journal:  Minerva Urol Nefrol        ISSN: 0393-2249            Impact factor:   3.720


  6 in total

Review 1.  Treatment of idiopathic membranous nephropathy.

Authors:  Julia M Hofstra; Fernando C Fervenza; Jack F M Wetzels
Journal:  Nat Rev Nephrol       Date:  2013-07-02       Impact factor: 28.314

Review 2.  Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.

Authors:  Thilo C von Groote; Gabrielle Williams; Eric H Au; Yizhi Chen; Anna T Mathew; Elisabeth M Hodson; David J Tunnicliffe
Journal:  Cochrane Database Syst Rev       Date:  2021-11-15

Review 3.  Membranous nephropathy in the older adult: epidemiology, diagnosis and management.

Authors:  Jeroen K J Deegens; Jack F M Wetzels
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

4.  Clinical outcomes and predictors for ESRD and mortality in primary GN.

Authors:  Yu-Hsiang Chou; Yu-Chung Lien; Fu-Chang Hu; Wei-Chou Lin; Chih-Chin Kao; Chun-Fu Lai; Wen-Chih Chiang; Shuei-Liong Lin; Tun-Jun Tsai; Kwan-Dun Wu; Yung-Ming Chen
Journal:  Clin J Am Soc Nephrol       Date:  2012-07-12       Impact factor: 8.237

5.  Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.

Authors:  Richard Phelps; Jonathan A Winston; Daniel Wynn; Mario Habek; Hans-Peter Hartung; Eva Kubala Havrdová; Glen S Markowitz; David H Margolin; Claudio E Rodriguez; Darren P Baker; Alasdair J Coles
Journal:  Mult Scler       Date:  2019-04-15       Impact factor: 6.312

6.  Intrarenal Transplantation of Hypoxic Preconditioned Mesenchymal Stem Cells Improves Glomerulonephritis through Anti-Oxidation, Anti-ER Stress, Anti-Inflammation, Anti-Apoptosis, and Anti-Autophagy.

Authors:  Hao-Hsiang Chang; Shih-Ping Hsu; Chiang-Ting Chien
Journal:  Antioxidants (Basel)       Date:  2019-12-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.